DBV Technologies to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) will participate in two investor events in March 2026: a fireside chat at Citizens Life Sciences Conference on March 10, 2026 at 1:40pm ET and one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026.
The Citizens presentation will be webcast live and a replay will be available on the company's Events page 90 days after the event.
Positive
- None.
Negative
- None.
Market Reaction – DBVT
Following this news, DBVT has gained 3.25%, reflecting a moderate positive market reaction. The stock is currently trading at $23.53. This price movement has added approximately $36M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
DBVT fell 5.94% while peers were mixed: CADL -0.8%, OMER -0.77%, CAPR -3.56% vs ANNX +2.38% and NGNE +7.75%, pointing to stock-specific pressure rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Phase 3 data update | Positive | -5.0% | Additional positive VITESSE Phase 3 data for VIASKIN Peanut Patch in children. |
| Feb 09 | Investor conference | Neutral | +7.1% | CEO fireside chat at Guggenheim biotech summit with webcast access. |
| Feb 05 | Capital structure update | Neutral | -0.9% | Disclosure of total shares and voting rights as of January 31, 2026. |
| Jan 16 | Financing proceeds | Positive | +0.5% | €166.7M gross proceeds from full exercise of March 2025 warrants. |
| Jan 12 | Capital structure update | Neutral | -5.0% | Updated total shares and voting rights as of December 31, 2025. |
Recent news often saw mixed or negative price reactions, including selloffs after both clinical and routine corporate updates.
Over the last few months, DBV Technologies has reported several notable events. A positive Phase 3 VITESSE update on Feb 10, 2026 was followed by a -5.04% move, while a Guggenheim investor summit participation on Feb 9, 2026 saw shares rise 7.11%. Capital from warrant exercises on Jan 16, 2026 produced a modest 0.53% gain. Routine voting-rights disclosures on Jan 12 and Feb 5, 2026 coincided with declines of -5.02% and -0.93%. Today’s conference participation fits this pattern of corporate updates with varied price responses.
Market Pulse Summary
This announcement highlights DBV Technologies’ plans to engage investors through March conferences, including a fireside chat on March 10, 2026 and meetings on March 11, 2026. In recent months, the company has reported positive Phase 3 data and strengthened its balance sheet via warrant exercises, alongside regular share and voting-rights updates. Investors may focus on how management frames clinical progress, capital needs, and commercialization plans during these events, as well as any subsequent regulatory or financing disclosures.
AI-generated analysis. Not financial advice.
Châtillon, France, March 4, 2026
DBV Technologies to Participate in Upcoming March Investor Conferences
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in March:
Citizens Life Sciences Conference – March 10, 2026
Format: Fireside Chat
Time: 1:40pm ET
Leerink Partners Global Healthcare Conference – March 11, 2026
Format: 1 on 1 Meetings
Sign up to watch the live webcast of the Citizens JMP presentation here. A replay will also be available on the Events section of the Company's website 90 days after the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
FAQ
When will DBVT present at the Citizens Life Sciences Conference in March 2026?
How can investors watch DBVT's Citizens Life Sciences Conference presentation on March 10?
What is DBVT's schedule for the Leerink Partners Global Healthcare Conference on March 11, 2026?
Will DBVT publish a replay of its March 10, 2026 presentation and when?
Where can investors find details about DBVT's March 2026 investor events and webcasts?
